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Cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA
sensor mediating innate antimicrobial immunity. It
catalyzes the synthesis of a noncanonical cyclic
dinucleotide, 20,50 cGAMP, that binds to STING and
mediates the activation of TBK1 and IRF-3. Activated
IRF-3 translocates to the nucleus and initiates the
transcription of the IFN-b gene. The structure of
mouse cGAS bound to an 18 bp dsDNA revealed
that cGAS interacts with dsDNA through two binding
sites, forming a 2:2 complex. Enzyme assays and
IFN-b reporter assays of cGAS mutants demon-
strated that interactions at both DNA binding sites
are essential for cGAS activation. Mutagenesis and
DNA binding studies showed that the two sites bind
dsDNA cooperatively and that site B plays a critical
role in DNA binding. The structure of mouse cGAS
bound to dsDNA and 20,50 cGAMP provided insight
into the catalytic mechanism of cGAS. These results
demonstrated that cGAS is activated by dsDNA-
induced oligomerization.
INTRODUCTION
Nucleic acids from bacteria and viruses induce potent immune
responses in infected mammalian cells (Barber, 2011a; Hemmi
et al., 2000; Kato et al., 2011; Keating et al., 2011). Microbial
DNA in the cytosol has long been known to induce innate
immune responses by stimulating the secretion of type I inter-
ferons (Barber, 2011a; Hornung and Latz, 2010; Ishii et al.,
2006; Stetson andMedzhitov, 2006). The endoplasmic reticulum
(ER) membrane-localized adaptor protein STING is essential for
the responses to cytosolic DNA (Barber, 2011b; Ishikawa and
Barber, 2008; Ishikawa et al., 2009; Sun et al., 2009; Zhong
et al., 2009). Recent studies have identified the cyclic GMP-
AMP (cGAMP) synthase (cGAS) as a cytosolic DNA sensor
upstream of STING (Sun et al., 2013). cGAS is activated upon
DNA binding and catalyzes the synthesis of a cyclic dinucleotide,
c[G(20,50)pA(30,50)p] (referred to as 20,50 cGAMP hereafter), fromImmATP and GTP (Ablasser et al., 2013; Diner et al., 2013; Gao
et al., 2013a). This dinucleotide in turn serves as a second
messenger to stimulate the induction of IFN-b via STING
(Ablasser et al., 2013; Diner et al., 2013; Wu et al., 2013). In
addition, STING is a direct sensor of bacterial cyclic dinucleo-
tides such as c-di-GMP and c-di-AMP, which are structurally
similar to 20,50 cGAMP (Burdette et al., 2011; Burdette and
Vance, 2013; Danilchanka andMekalanos, 2013). Ligand binding
by STING induces the recruitment of the protein kinase TBK1
and transcription factor IRF-3 to the signaling complex (Tanaka
and Chen, 2012). Phosphorylation of IRF-3 by TBK1 at the
signaling complex on STING promotes the oligomerization of
IRF-3 and its translocation into the nucleus, where it activates
the transcription of the IFN-b gene together with the transcription
factor NF-kB (Fitzgerald et al., 2003; Tanaka and Chen, 2012).
The critical role of cGAS in antiviral immunity and cytosolic
DNA sensing has been confirmed by recent studies of cGAS-
deficient mice (Li et al., 2013).
Although the identity of the cGAS product has been
intensively studied (Ablasser et al., 2013; Diner et al., 2013;
Gao et al., 2013a) and the structures of mouse and porcine
cGAS bound to double-stranded DNA (dsDNA) have been
determined (Civril et al., 2013; Gao et al., 2013a), the mecha-
nism of cGAS activation by dsDNA is still not fully understood.
To address this question, we have determined the crystal
structures of human cGAS (hcGAS) in isolation and of mouse
cGAS (mcGAS) bound to an 18 bp dsDNA. Our structures
showed that cGAS forms a 2:2 complex with dsDNA instead
of the 1:1 complex as described in previous studies (Civril
et al., 2013; Gao et al., 2013a). We have confirmed the self-
assembly of cGAS in the presence of dsDNA in solution by
analytical ultracentrifugation (AUC) and small-angle X-ray
scattering (SAXS). Enzyme assays and DNA binding studies
of cGAS mutants demonstrated that dsDNA binding-induced
dimerization is required for cGAS activation. These results
provide insight into the mechanism of cGAS activation by
dsDNA, which is central to its function in innate immunity. In
addition, our structure of mcGAS bound to dsDNA and
20,50 cGAMP provided insight into the catalytic mechanism of
the enzyme. Furthermore, we have demonstrated that 20,50
cGAMP binds to STING with higher affinity compared to
canonical cyclic dinucleotides and potently stimulates the
expression of IFN-b in cells.unity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc. 1019
Figure 1. cGAS Is Activated by dsDNA and Catalyzes the Synthesis of 20,50 cGAMP, a High-Affinity Ligand for STING
(A) cGAS activity assay by ion exchange chromatography. The reaction product was first purified by ultrafiltration and then analyzed with a MonoQ 5/50 GL
column. Salmon sperm DNA at 0.2 mg/ml was used to stimulate mcGAS catalytic domain at 10 mM concentration.
(B) The catalytic activity of cGAS is dependent on the length of dsDNA. Reaction products from mcGAS stimulated with different dsDNA were analyzed by ion
exchange chromatography. The enzyme and DNA concentrations used in these assays are 10 and 50 mM, respectively.
(C) Binding study of mcGAS catalytic domain with a 20 bp dsDNA by isothermal titration calorimetry (ITC).
(D) Binding study of 20,50 cGAMP with human STING ligand binding domain by ITC.
(E) 20,50 cGAMP stimulates the secretion of IFN-b in human THP-1 cells. The concentration of IFN-b in the culture supernatant was analyzed by ELISA at 4 and 8 hr
after stimulation. 30,50 cGAMP was used as a control. The concentration of 20,50 or 30,50 cGAMP used in these assays is 25 mg/ml. The error bars represent the
standard deviations of signals from four independent measurements.
See also Figure S1.
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cGAS Is Activated by dsDNA and Catalyzes the
Synthesis of a High-Affinity Ligand for STING
We have expressed and purified both human and mouse cGAS
catalytic domains and conducted extensive biochemical char-
acterization of the enzymes. First, we conducted enzymatic
activity assays ofmcGASwith andwithout dsDNA.mcGAS cata-
lyzed the synthesis of a new dinucleotide in the presence of ATP,
GTP, and dsDNA (Figure 1A). In contrast, no dinucleotide was
produced in the absence of dsDNA. Consistent with previous
studies, mass spectrometry analysis showed that the mass of
the product is675 Dalton. We observed that the cGAS product1020 Immunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Indid not elute at the position expected for 30,50 cGAMP on a
MonoQ ion exchange column (Figure S1A available online), indi-
cating that the product of cGAS is not 30,50 cGAMP. Consistent
with this observation, others have shown that the product of
cGAS is 20,50 cGAMP instead of 30,50 cGAMP (Ablasser et al.,
2013; Diner et al., 2013; Gao et al., 2013a).
Next, we examined whether cGAS activity is dependent on
the length of dsDNA. We found that dsDNA of 12 bp in length
did not activate mcGAS efficiently (Figure 1B), whereas dsDNA
of 18 bp in length had about 90% activity compared to salmon
sperm DNA (Figure 1B), which is used routinely to study
dsDNA-mediated immune responses in transfected cells.
Longer dsDNA oligonucleotides of 20 bp had activityc.
Figure 2. Structure of Human cGAS Cata-
lytic Domain
(A) Ribbon representation of the structure of
hcGAS catalytic domain. The Zn2+ ion is shown by
the red sphere.
(B) Structure of the hcGAS dimer in the crystallo-
graphic asymmetric unit.
(C) Comparison of ligand-free human (green, PDB
4LEV), mouse (blue, PDB 4K8V), and porcine
(salmon, PDB 4JLX) cGAS dimer structures.
(D) Superposition of ligand-free human, mouse,
and porcine cGAS dimers rainbow-colored
according to B-factors of the Ca atoms. Atoms in
red have higher B-factors and atoms in blue have
lower B-factors.
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Structural Insight of cGAS Activationcomparable to salmon sperm DNA (Figure 1B). Isothermal titra-
tion calorimetry (ITC) showed that mcGAS catalytic domain
binds a 20 bp dsDNA with an affinity of 20 mM (Figure 1C).
Because of the relatively low affinity, we did not observe DNA
binding by cGAS catalytic domain by gel filtration chromatog-
raphy. Furthermore, we used gel filtration chromatography to
study the binding of 20,50 and 30,50 cGAMP to the ligand-binding
domain of human STING. We observed almost stoichiometric
binding of 20,50 cGAMP to STING (Figure S1B), whereas we
consistently observed a significant population of free 30,50
cGAMP in the binding studies (Figure S1C). Consistent with
these observations, binding studies by ITC showed that STING
binds 20,50 cGAMP at 60 nM affinity (Figure 1D), whereas 30,50
cGAMP binds STING at3 mMaffinity (Figure S1D). 20,50 cGAMP
also induced higher amounts of IFN-b in human THP-1 cells
compared to 30,50 cGAMP (Figure 1E). These studies demon-
strated that cGAS is activated by dsDNA and catalyzes the syn-
thesis of 20,50 cGAMP, a high-affinity ligand for STING.
cGASExhibits a Similar Fold asOAS1 and Forms aDimer
in the Crystal
To elucidate the structural basis of cGAS activation by dsDNA,
we have crystallized hcGAS catalytic domain in two crystal forms
and determined their structures at 2.0 A˚ resolution by single-
wavelength anomalous dispersion (SAD) by using Se-Met deriv-
ative crystals. Statistics of the crystallographic analysis are
shown in Table S1. The structure of the cGAS catalytic domain
(referred to as ‘‘cGAS’’ hereafter) has a bilobed structure (Fig-
ure 2A), similar to that of 20-50-oligoadenylate synthase (OAS1,Immunity 39, 1019–1031, Dermsd of 3.1 A˚) (Hartmann et al., 2003).
The overall structures of the four cGAS
molecules in the two crystal forms are
similar, with rmsd of 0.6 to 1.1 A˚ in pair-
wise comparisons.
The N-lobe of cGAS has a canonical
nucleotidyltransferase (NTase) fold (Fig-
ure 2A). The C-lobe contains a tight five-
helix bundle (Figure 2A). The long helices
(a1a and a1b) at the N terminus of the
cGAS catalytic domain span the two
lobes. The active site of cGAS is located
on the edge of the deep groove between
the N-lobe and C-lobe (Figures 2A and2B). Mutations of any of the three conserved catalytic residues
E225, D227, or D319 to alanine disrupted the catalytic activity
of cGAS (data not shown). Unlike OAS1, cGAS has a unique
zinc-binding site in a long loop between helices a4 and a5
(Figure 2A). This loop connects the two lobes and mediates the
dimerization of two cGAS molecules in the crystal (Figure 2B).
Residues H390, C396, C397, and C404 coordinate Zn2+ with
tetrahedral geometry. The identity of this structural zinc was
confirmed by inductively coupled plasma mass spectrometry
(ICP-MS).
Although the hcGAS catalytic domain is monomeric in
solution, it forms noncrystallographic symmetry-related dimers
in the two forms of crystals (Figure 2B). Similar dimers were
also observed in a hexagonal crystal obtained from a high salt
(1.5 M sodium citrate) condition. In addition, the previously
described ligand-free mouse and porcine cGAS form similar
dimers in the crystals (Figure 2C). The overall structures of
DNA-free human, mouse, and porcine cGAS dimers are similar,
with some structural differences in the NTase domains (Fig-
ure 2C). The structures of the NTase domains of hcGAS in
both crystal forms are quite flexible and have average B-factors
almost twice that of the C-lobes (Figure 2D). Similar to human
cGAS, the NTase domains of mouse and porcine cGAS are
also quite flexible and have significantly higher B-factors
compared to C-lobes (Figure 2D).
The total buried surface area at the hcGAS dimer interface
is1,330 A˚2, which is within the range (1,600 ± 400 A˚2) of typical
protein-protein interfaces (LoConte et al., 1999). Interactions be-
tween the two cGAS molecules are mediated by 15 main-chaincember 12, 2013 ª2013 Elsevier Inc. 1021
Figure 3. The Structural Basis of cGAS Acti-
vation by dsDNA
(A) Crystal structure of mcGAS catalytic domain
bound to an 18 bp dsDNA. Ribbon representations
of the 2:2 mcGAS:dsDNA complex structure in
two different orientations.
(B) Electrostatic surface potential of the mcGAS
dimer in the mcGAS:dsDNA complex. Positively
charged surface is colored blue, and negatively
charged surface red. The two dsDNA bound to the
cGAS dimer are shown by ribbon representations.
(C) Electrostatic surface potential at the DNA
binding sites of a mcGAS monomer. The two
dsDNA bound to mcGAS are shown by the cyan
and purple stick models.
(D) Comparison of the 2:2 mcGAS:dsDNA com-
plex structure with the 1:1 OAS1:dsRNA complex
structure (PDB 4IG8).
(E) Superposition of four cGAS:dsDNA complex
structures. Structure of mcGAS bound an 18 bp
dsDNA (this work, PDB 4LEY) is in green; mcGAS
bound to a 16 bp dsDNA (PDB 4K96) in yellow;
mcGAS bound to a 16 bp dsDNA and pppG(20,50)
pG (PDB 4K98) in magenta; porcine cGAS bound
to a 14 bp dsDNA (PDB 4KB6) in cyan. The dsDNA
bound to cGAS are shown by the orange ribbons.
(F) Superposition of three mcGAS:dsDNA com-
plex structures (PDB 4LEY, 4K96, and 4K98). The
proteins are rainbow-colored according to B-
factors of the Ca atoms. Atoms in red have higher
B-factors and atoms in blue have lower B-factors.
See also Figure S2.
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Structural Insight of cGAS Activationand side-chain hydrogen bonds. Residues N389 through E398
in the loop containing the Zn2+ binding site contribute to dimer
formation. In addition, residues A346 and K347 form two
hydrogen bonds with the side chain of E398 via their main chain
amine groups. Residues K347, K394, and E398 that mediate
dimer formation are conserved in the sequences of hcGAS
and mcGAS. These structural studies showed that cGAS cata-
lytic domain exhibits a similar fold as OAS1 and forms a dimer
in the crystals.1022 Immunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc.The Structural Basis of cGAS
Activation by dsDNA
To elucidate the structural basis of cGAS
activation by DNA, we have crystallized
the catalytic domain of mcGAS bound
to an 18 bp palindromic dsDNA and
determined the structure of the complex
at 2.5 A˚ resolution (Table S1). Two 2:2
mcGAS:dsDNA complexes with similar
structures were observed in the crystallo-
graphic asymmetric unit (Figure 3A). DNA
binding by cGAS is not sequence depen-
dent. The four mcGAS molecules in the
two 2:2 complexes bind to three different
regions of the 18 bp dsDNA (Figures S2A–
S2C). Superposition of the four cGAS:
dsDNA complexes formed at the primary
DNA binding site (site A) shows that each
of the cGAS molecules interacts with thedsDNA in a similar manner but contacts different sequences
of the 18 bp dsDNA. Two dsDNA molecules crosslink a cGAS
dimer, forming a 2:2 complex (Figure 3A). Each cGAS molecule
interacts with the two dsDNA molecules through two binding
sites (Figures 3A and S2D). The buried surface areas between
cGAS(A) and the two dsDNA duplexes are 1,380 A˚2 (dsDNA
EF, site A) and 930 A˚2 (dsDNA IJ, site B), respectively. Similarly,
the buried surface areas between cGAS(C) and the two dsDNA
duplexes are 1,540 A˚2 (dsDNA IJ, site A) and 790 (dsDNA EF,
Immunity
Structural Insight of cGAS Activationsite B) A˚2, respectively. Site B contributes 34%–40% of the
total buried surface area between cGAS and the dsDNA. The
surface electrostatic potential of the cGAS dimer shows comple-
mentarity to the two negatively charged dsDNA (Figures 3B and
3C). Although the cGAS dimers are nearly symmetrical, they bind
to the dsDNA in an asymmetrical manner (Figure 3A). Rotation of
the complex structures along the two-fold axis of cGAS dimer
shows that the two dsDNA fragments bound to cGAS are related
to each other by translations of 4 bp (dsDNA EF and IJ) or 5 bp
(dsDNA KL and GH) along the helical axis of the DNA. This
arrangement of the dsDNA relative to the cGAS dimers avoids
clashes between the two dsDNA duplexes within the complex
(Figure S2E). This also suggests that the cGAS dimer cannot
bind to the middle of two long dsDNA without clashes between
the two DNA molecules. Instead, the cGAS dimers probably
bind to the terminal regions of two dsDNA pointing in different
directions (Figure S2E). The 2:2 mcGAS:dsDNA complex struc-
ture differs significantly from the OAS1:dsRNA complex. OAS1
binds to dsRNA in a similar way as cGAS binds to dsDNA
at site A (Figure 3D) but forms only a 1:1 complex (Donovan
et al., 2013). No higher-order structure was observed in the
OAS1:dsRNA complex structure (Donovan et al., 2013).
More compelling evidence about DNA binding-induced dimer-
ization of cGAS comes from the seven different structures of
mouse and porcine cGAS bound to dsDNA published recently
(Civril et al., 2013; Gao et al., 2013a). In all these structures,
cGAS forms 2:2 complexes with dsDNA that are similar to those
observed in our mcGAS:DNA complex structures through either
crystallographic (PDB 4K97, 4K98, 4K99, 4K9A, 4K9B, and
4KB6) or noncrystallographic (PDB 4K96) packing contacts
(Figure 3E). Together with two of our structures (PDB 4LEY and
4LEZ), in which mcGAS forms 2:2 dimers with DNA through
noncrystallographic packing contacts, nine structures in five
different space groups showed that cGAS and dsDNA com-
plexes form similar 2:2 dimers in crystals. These structures
suggest that it is unlikely that dsDNA-induced cGASdimerization
is an artifact of crystal packing interactions. Unfortunately, the
functional significance of DNA-induced dimerization of cGAS
as well as DNA binding at site B were not explored in any previ-
ous studies (Civril et al., 2013; Gao et al., 2013a), perhaps
because six out of the seven published 2:2 cGAS:DNA dimer
structures are formed by crystallographic symmetry-related
molecules.
cGAS interacts with the dsDNA through extensive electro-
static interactions and hydrogen bonds (Figure S2D). At the
interface between cGAS(C) and dsDNA (IJ, site A), residues
K151, R158, R180, K184, K372, and K395 form salt bridges
with the phosphate backbone of the DNA (Figure S2D). In
addition, the side chain of R161 reaches into the minor groove
of the DNA. Moreover, the side chains of S165, N196, and
Y200 form three hydrogen bonds with the phosphate backbone.
Residues K160, A168, and H203 exhibit van der Waals contacts
with the DNA. Most of these interactions are mediated by base
pairs 2 to 12 of the dsDNA (Figure S2D). Interactions between
cGAS(A) and DNA (IJ, site B) are less extensive as reflected by
the smaller buried surface area at this interface (Figure S2D).
Residues R222 and K335 form two salt bridges with the phos-
phate backbone of the DNA (Figure S2D). In addition, the side
chain of R342 reaches into the minor groove of the dsDNA butImmdoes not interact with the phosphate backbone (Figure S2D).
Moreover, T338 forms a hydrogen bond with the phosphate
group of dA9. Interactions between cGAS dimer (AC) and the
other dsDNA (EF) are similar to its interactions with dsDNA (IJ).
The dimerization of mcGAS is mediated by hydrogen bonds at
the dimer interface. Residues K382 and E386 at the Zinc-binding
loop mediate the dimerization of mcGAS.
Comparison of the DNA-bound mcGAS structure and the
ligand-free mcGAS structure revealed that DNA binding induced
substantial conformational changes in the active site of cGAS
(Figure S2F). Residues E211, D213, and D307 in the active site
of mcGAS are realigned upon dsDNA binding (Figure S2G). In
addition, the loop connecting helix a1b and b1 is restructured
upon DNA binding. It has been shown that residue S199 in this
restructured loop interacts with the g phosphate group of the
substrate ATP or GTP (Gao et al., 2013a). These conformational
changes in response to DNA binding probably contribute to the
activation of cGAS. Furthermore, comparison of the ligand-free
and DNA-bound mcGAS dimer structures shows that DNA bind-
ing opens instead of closes the cGAS dimer structure (Fig-
ure S2H). As indicated by the uniform distribution of B-factors
in the NTase domains and C-lobes of three mcGAS:DNA com-
plex structures (Figure 3F), DNA binding dramatically reduced
the structural flexibility of the NTase domain. Crosslinking of
the cGAS dimer by dsDNA appears necessary for the activation
of cGAS by stabilizing the catalytically active conformation of the
enzyme. In summary, the structure of mcGAS bound to the 18 bp
dsDNA revealed that crosslinking of cGAS dimers by dsDNA
molecules mediates the activation of cGAS.
DNA Binding by cGAS Induces Higher-Order Complex
Formation in Solution
To determine whether cGAS catalytic domain forms the 2:2
complex in solution as was observed in the crystal structures,
we conducted small-angle X-ray scattering (SAXS) studies of
mcGAS in isolation and in complex with a 20 bp dsDNA. The
SAXS data showed a significant difference in the small-angle
X-ray scattering of mcGAS with and without the 20 bp dsDNA
(Figure 4A). In the presence of dsDNA, the pair distance distribu-
tion function shifts to longer distances (Figure 4B), indicating the
formation of a larger size complex. The radii of gyration (Rg) for
cGAS in isolation and for the cGAS:DNA complex are 24.6 and
33.0 A˚, respectively (Figure 4C). The calculated Rg values from
the crystal structures are 22.2 A˚ for cGAS in isolation and
30.4 A˚ for the cGAS:DNA complex (Figure 4C), both of which
are close to experimental values but slightly smaller, partially
as a result of omitting the possible solvation layers in the calcu-
lations. The concentration-normalized X-ray forward scattering,
i.e., Io/Cmass, is an indicator of molecular weight, where Io is the
forward scattering and Cmass is the sample concentration in
mg/ml. The ratio of concentration-normalized forward scattering
between samples of cGAS with and without dsDNA is about 2.5
(Figure 4C), which is close to the theoretical value of 2.8 for the
2:2 cGAS:DNA complex versus cGAS in isolation. These results
support the theory that mcGAS forms a 2:2 complex with dsDNA
in solution. Themolecular envelope of cGAS in isolationmatches
the structure of monomeric cGAS (Figure 4D, left). Themolecular
envelope for the cGAS:DNA complexmatcheswell with the crys-
tal structure of the 2:2 mcGAS:DNA complex (Figure 4D, right).unity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc. 1023
Figure 4. DNA Binding by cGAS Induces Higher-Order Complex Formation in Solution
(A) Small-angle X-ray scattering (SAXS) data of mcGAS catalytic domain (red) and its complex with a 20 bp dsDNA (blue).
(B) Normalized pair distance distribution function (PDDF) for mcGAS alone (red) and for mcGAS:DNA complex (blue).
(C) Guinier fits (red lines) of SAXS data for mcGAS alone (open cycles) and its complex with DNA (open squares). The SAXS data were normalized by the mass
concentration of the samples. The fitted q ranges were limited to qmax*Rg < 1.3. Io is the forward scattering, i.e., scattering intensity at q = 0. Cmass is the
concentration of the samples in mg/ml.
(legend continued on next page)
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Structural Insight of cGAS ActivationAnalytical ultracentrifugation (AUC) analysis showed that
mcGAS in isolation at 200 mM is mostly monomeric with a
very small fraction of dimers (Figure 4E). When cGAS
(150 mM) bound to dsDNA, it formed a range of species
including 2:2 dimers and higher oligomers (Figures 4E and 4F
and Table S2). Oligomer formation is sensitive to both protein
and DNA concentration, as shown by the fact that a 5-fold
dilution of the sample (30 mM of cGAS) results in dissociation
of the oligomers, reflecting weak dimerization as well as the
low affinity between cGAS and dsDNA. Clues into the formation
of higher-order cGAS:dsDNA oligomers are suggested by the
observed crystal packing. Each DNA duplex in the crystal stacks
end-to-end with another duplex to mimic a continuous, 36 bp
dsDNA (Figure S2E). In addition, we have tested how mutations
at the dimer interface and the DNA binding sites affect the olig-
omerization of cGAS. The replacement of K382 by alanine at
the dimer interface disrupted the dsDNA-induced oligomeri-
zation of cGAS (Figure 4E). Moreover, mutations K372E or
R158E at site A and mutations R335E or R342E at site B also
abolished the oligomerization of cGAS in presence of the
20 bp dsDNA (Figure 4G). These results confirmed that dsDNA
binding induces the oligomerization of cGAS in solution. DNA
binding at both site A and site B is essential for higher-order
complex formation.
Mutations at the DNA Binding Sites and the Dimer
Interface Affect cGAS Activity
The crystal structure of the 2:2 mcGAS:dsDNA complex pro-
vides a new model of cGAS activation by dsDNA. To test this
model, we generated 18 mutants of the mcGAS catalytic
domain, purified each of the mutant proteins, and conducted
enzyme activity assays. Replacement of R158, K160, R161,
S165, K372, and K395 at site A with glutamates significantly
reduced cGAS activity (Figures 5A and S3A). In contrast, the
replacement of K151, K162, and R180 at site A only moderately
reduced the activity of cGAS (Figures 5A andS3A). A substitution
of K184, which does not contact the DNA directly, had no affect
the catalytic activity of cGAS (Figures 5A and S3A). Replacement
of R222, K240, and K323 at site B also resulted inmore than 50%
reduction of cGAS activity (Figures 5A and S3A). In contrast, the
replacement of K315, which does not interact with DNA directly,
resulted in only30% reduction of activity (Figures 5A and S3A).
Strikingly, substitutions of either K335 or R342 at site B with
glutamate nearly abolished the activity of cGAS (Figures 5A
and S3A), demonstrating that DNA binding at site B is also
required for the activation of cGAS.
To test whether dimer formation is also needed for cGAS
activity, we replaced K382 or E386 at the dimer interface with
alanine. These two mutations resulted in nearly complete loss
of cGAS activity (Figures 5A and S3A). The replacement of
K394 in hcGAS, which corresponds to K382 in mcGAS, also(D) Overlays of the crystal structures (cartoon) and SAXS molecular envelope (m
(E) Sedimentation velocity AUC analysis of WT and K382A mutant of mcGAS in
mass estimates listed. The K382A dimer interface mutant formed a 1:1 complex
(F) Size-and-shape distribution analysis of theWTmcGAS:dsDNA sample reveals
oligomeric species are identified based on experimentally determined molecular
(G) Normalized sedimentation velocity AUC analysis of site A (K372E and R158E
dsDNA. The WT mcGAS distribution is shown for comparison.
Immabolished the catalytic activity (Figure S3B). Consistent with
cGAS dimerization being required for enzymatic activity, AUC
analysis of the K382A mutant of mcGAS shows that this mutant
cannot form dimers or higher-order oligomers with a 20 bp
dsDNA (Figure 4E). Notably, mutant K382A still binds dsDNA
and forms a 1:1 complex (Figure 4E), which is obviously not
sufficient for cGAS activation (Figure 5A). Moreover, the replace-
ment of K335, which forms a salt bridge with E386 at the mcGAS
dimer interface and contacts the DNA at site B, also disrupted
cGAS activity (Figure 5A).
To determine the physiological relevance of our structural
analysis, we examined whether mutations at the two DNA
binding sites and the dimer interface of mcGAS affect signal
transduction in cells. Wild-type mcGAS activated the IFN-b
promoter in the presence of increased concentration of mSTING
(Figure 5B). Three independent substitutions at site A (R158E,
K372E, and K395E) dramatically decreased the mcGAS activ-
ities whereas mutant K184E had activity similar to that of wild-
type. Two substitutions at site B (K335E, and R222E plus
R342E) also decreased signaling to background whereas
mutants R222E, K240E, or R342E with single amino acid sub-
stitutions in site B did not affect reporter activity (Figure 5B).
Importantly, substitutions at the dimer interface (K382A and
E386A) were defective for the mcGAS activity (Figure 5B). In
addition, all of these mutations affected firefly luciferase reporter
activity from an NF-kB promoter in a similar manner to that of
IFN-b reporter (Figure S3C). The activities of most of the mutants
correlate with enzymatic activities of mcGAS catalytic domain,
exceptmutants R222E andR342E, perhaps because the defects
are not significantly strong to be detectable in cells. However,
mutation of both residues at the same time disrupted cGAS-
mediated signaling in cells (Figure 5B). The locations of the
mutated residues on the surface of mcGAS and their effects on
the activity of cGAS were summarized schematically in Fig-
ure 5C. In conclusion, these studies demonstrated that muta-
tions at the two DNA binding sites and the dimer interface affect
cGAS activity in vitro and signaling in cells, suggesting that
dsDNA-induced oligomerization of cGAS is essential for its
activity.
cGAS Binds dsDNA Cooperatively through the Two
Binding Sites
Although the results of biochemical and cell-based assays
demonstrated that mutations at both site A and site B affect
cGAS function, it is not clear how these mutations affect DNA
binding. To further explore the mechanism of cGAS activation
by dsDNA, we have purified all the mutants of mcGAS catalytic
domain described above and conducted DNA binding studies
by electrophoretic mobility shift assays (EMSA) via a 45 bp inter-
feron stimulatory DNA (ISD). First, we conducted DNA binding
assays for wild-typemcGAS and each of themutants individuallyesh) for mcGAS in isolation (left) and mcGAS:DNA complex (right).
the absence and presence of a 20 bp dsDNA, with experimentally determined
with dsDNA but did not oligomerize.
a complicated mixture of compact and elongated oligomeric species. Putative
weights in Table S2.
) and site B (R342E and K335E) mcGAS mutants in the presence of a 20 bp
unity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc. 1025
Figure 5. Mutations at the DNA Binding Sites and the Dimer Inter-
face Affect cGAS Activity
(A) Enzyme activities ofmcGASmutants. The activities of wild-type andmutant
mcGAS were analyzed by ion exchange chromatography. The activities of the
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1026 Immunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inby titrating 1 mMDNA with 5 to 80 mM of the protein (Figures 6A–
6M and S4A–S4H). The DNA binding studies showed that muta-
tions K151E, R158E, and S165E at site A only slightly reduced
DNA binding and did not affect dimer or higher order complex
formation (Figures 6B, S4C, and S4E). Mutations K160E,
K162E, K372E, and K395E at site A reduced DNA binding, but
did not disrupt dimer or higher-order complex formation as
well (Figures 6C, 6F, 6G, and S4D). In contrast, mutations
R180E and K184E reduced DNA binding and higher-order com-
plex formation (Figures 6E and S4F). Because multiple residues
are involved in DNA binding at site A, mutations of individual
residues did not affect DNA binding or higher-order complex
formation dramatically. These results are consistent with the
observation that mutations of hcGAS at site A do not affect
DNA binding significantly (Civril et al., 2013). Unexpectedly, how-
ever, site B plays a much more important role in DNA binding
compared to site A. Mutations of any residues at site B dramat-
ically reduced DNA binding as well as higher-order complex
formation (Figures 6H–6K, S4G, and S4H). Mutations R222E
and K240E severely reduced DNA binding (Figures 6H and 6I).
Mutations K315E, K323E, K335E, and R342E also dramatically
reduced DNA binding and higher-order complex formation
(Figures 6J, 6K, S4G, and S4H). In addition, mutation K382A at
the dimer interface also reduced DNA binding and higher-order
complex formation (Figure 6L). In contrast, mutation E386A at
the dimer interface did not affect DNA binding significantly (Fig-
ure 6M). We have also conducted DNA binding studies for all the
mutants together at DNA concentrations of 10, 20, and 50 mM
and obtained similar results (Figures 6N, S4I, and S4J). Further-
more, we observed that the inclusion of 5 mM EDTA in the bind-
ing studies abolished DNA binding by cGAS (Figure S4B),
demonstrating that zinc binding is critical for the structural integ-
rity of cGAS.
Although wild-type full-length mcGAS is not stable and
degrades readily during purification, we have successfully puri-
fied eight mutants of full-length mcGAS and conducted DNA
binding studies and enzyme assays (Figures S4K–S4T). Similar
to the results from the DNA binding studies via mcGAS catalytic
domain, mutations R158E or K372E at site A aswell asmutations
K382A or E386A at the dimer interface have only limited impact
on DNA binding (Figures S4K, S4L, and S4Q–S4S). In contrast,
mutations R222E, K240E, K335E, and R342E at site B dramati-
cally reduced DNA binding and oligomerization of cGAS (Figures
S4M–S4P and 4S). Enzyme assays showed that mutationsmutants relative to the wild-type enzyme were calculated based on the peak
areas of 20,50 cGAMP in the chromatograms.
(B) IFN-b luciferase reporter assays in HEK293T cells transfected with mouse
STING and cGAS. Error bars represent the standard deviations of signals from
three independent transfections. The upper panel shows the mRNA levels of
mcGAS and its mutants in the transfected cells. The mRNA levels were
determined after 20 cycles of RT-PCR amplification. GAPDH mRNA was
amplified as an internal control.
(C) Locations of the mutated residues on the surface of mcGAS and effects of
these mutations on cGAS activity. The two dsDNAs bound to cGAS are shown
by the cyan and purple stick models. Residues mutated at site A are colored
magenta and those in site B are colored blue. Residues at the dimer interface
are colored green. Mutations that caused more than 80% loss of enzyme
activity (in A) are underlined.
See also Figure S3.
c.
Figure 6. cGAS Binds dsDNA Cooperatively through Two Binding Sites
(A) DNA binding study of WT mcGAS catalytic domain by electrophoretic mobility shift assay (EMSA). The concentration of the 45 bp interferon stimulatory DNA
(ISD) used in this study is 1 mM and the protein concentrations are from 5 to 80 mM.
(B–G) DNA binding studies of site A mutants of mcGAS.
(H–K) DNA binding studies of site B mutants.
(L and M) DNA binding studies of mutants at the dimer interface.
(N) DNA binding study of 18 mcGAS mutants together on one gel.
The DNA concentration used in this study is 1 mM and mcGAS is at 20 mM. See also Figure S4.
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dimer interface dramatically reduced the activity of full-length
mcGAS (Figure S4T). In agreement with results from the IFN-b
reporter assays (Figure 5B), mutations R222E, K240E, and
R342E at site B had only limited impact on the enzymatic activity
(Figure S4T).
These mutagenesis and DNA binding studies showed that
site B plays an important role in DNA binding and higher-order
complex formation by cGAS. It is most likely that DNA binding
to cGAS at sites A and B is cooperative and that the dimerization
of cGAS facilitates the cooperative DNA binding. Althoughmuta-Immtions at site A did not influence the cooperative DNA binding
significantly, mutations at site B dramatically reduced the coop-
erative binding of DNA. AUC studies of mcGAS mutants
confirmed the importance of DNA binding at site B for cGAS as-
sembly. The site B mutants K335E and R342E were incapable of
assembly and formed only 1:1 complexes with DNA (Figure 4G).
In contrast, site Amutant K372E could assemble into larger com-
plexes, although higher assembly was diminished compared to
WT cGAS (Figure 4G). Altogether, these results demonstrated
that cGAS binds dsDNA cooperatively through two binding sites
and that siteBplays a critical role in the cooperativeDNAbinding.unity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc. 1027
Figure 7. Structure of mcGAS Bound to
dsDNA and 20,50 cGAMP
(A) Ribbon representation of mcGAS bound to an
18 bp dsDNA and 20,50 cGAMP. The dinucleotide
is shown by the yellow ball-and-stick model.
Catalytic residues and residues that interact with
20,50 cGAMP are shown by the gray ball-and-stick
models. For clarity, the two dsDNA bound to
mcGAS are not shown.
(B) Close-up view of 20,50 cGAMP bound to
mcGAS.
(C) Difference maps of 20,50 cGAMP bound to
mcGAS in three different orientations. The sA
weighted Fo  Fc map calculated without the
ligand is contoured at 3.5s. 20,50 cGAMP is shown
by the yellow ball-and-stick model.
(D) Comparison of structures of pppG(20,50)pG
(blue sticks) and 20,50 cGAMP (yellow sticks)
bound to mcGAS. The figure was generated by
superposition of mcGAS bound to pppG(20,50)pG
(PDB 4K98) onto the complex structure of mcGAS
bound to 20,50 cGAMP (this work, PDB 4LEZ). The
structure of mcGAS determined in this work is
shown by the cyan and purple ribbons. Residues
at the active site of mcGAS are shown by the gray
stick models.
(E) Comparison of structures of 20,50 cGAMP
bound to mcGAS in two different orientations. This
figure was generated by superposition of a
previously determined cGAS:DNA:20,50 cGAMP
complex structure (PDB 4K9B) onto the complex
structure from this work (PDB 4LEZ).
See also Figure S5.
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Structural Insight of cGAS ActivationStructure of mcGAS Bound to dsDNA and 20,50 cGAMP
To elucidate the catalytic mechanism of cGAS, we have deter-
mined the 2.36 A˚ resolution structure of mcGAS catalytic domain
bound to dsDNA and 20,50 cGAMP (Figures 7A, 7B, and S5A). The
ternary complex crystallized in orthorhombic space group
P212121 with one 2:2:2 cGAS:dsDNA:2
0,50 cGAMP complex in
the asymmetric unit (Table S1). The difference (Fo  Fc) map
shows well-defined electron density for 20,50 cGAMP at one
binding site (Figure 7C), whereas the density at the second
binding site is fragmented. The difference map shows clear fea-
tures of the 20,50 phosphodiester bond between G and A and the
30,50 phosphodiester bond between A and G (Figure 7C). The
adenine base forms three hydrogen bonds with the side chains
of R364 and S366. The 20 hydroxyl of the adenylate forms two1028 Immunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc.hydrogen bonds with catalytic residues
D213 and D307. The 30,50 phosphodiester
bond between A and G is positioned near
the catalytic residues D213 and D307.
Because the phosphate of the A:G link-
age is close to the catalytic residue
D213 (3.15 A˚, Figure 7B), this structure
is likely to be unstable in solution. Con-
sistent with this prediction, the second
product-binding site is poorly occupied
because of exposure to solvent. The
structure and orientation of 20,50 cGAMP
observed in our structure is similar tothat of the 50-pppG(20,50)pG, 50-pppdG(20,50)pdG, and 50-
pG(20,50)pA (Gao et al., 2013a) bound to mcGAS reported
previously (Figures 7D, S5B, and S5C). However, our ternary
complex structure with 20,50 cGAMP is strikingly different from
the structure reported by Gao et al. (2013a) (Figure 7E). The
product observed in the structure reported by Gao et al.
(2013a) has the guanine and adenine bases flipped relative to
our structure and the phosphate ribose ring moved away from
the active site of cGAS (Figure 7E). Superposition of the two
structures clearly showed that the difference map we observed
could not be interpreted by the 20,50 cGAMP structure reported
by Gao et al. (2013a). In our structure, the guanine ring of 20,50
cGAMP stacks against the phenol ring of Y421 (Figure 7B),
whereas in the structure reported by Gao et al. (2013a), the
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Y421. According to the proposed catalytic mechanism of
cGAS (Gao et al., 2013a), it is likely that our structure shows
how 20,50 cGAMP binds to cGAS immediately after the formation
of the 30,50 phosphodiester bond, whereas the structure
observed byGao et al. (2013a) probably shows how 20,50 cGAMP
binds cGAS before its release from the active site. In summary,
the structure of cGAS bound to DNA and 20,50 cGAMP confirmed
the identity of cGAS product and provided insight into the cata-
lytic mechanism of the enzyme.
DISCUSSION
Based on the crystal structures of cGAS catalytic domain in
isolation, in complex with dsDNA, and in complex with dsDNA
and 20,50 cGAMP plus results from our biophysical, biochemical,
and cell-based studies, we propose the following model for
cGAS activation by dsDNA. cGAS is monomeric in isolation
and does not have catalytic activity as a result of local destabili-
zation of the structure of the NTase domain and the active site.
DNA binding induces conformational changes in cGAS and
crosslinks two cGAS molecules to form a 2:2 dimer or higher-
order complexes, resulting in the activation of cGAS. Site A
plays a major role in inducing the conformational changes of
cGAS in response to contacts with DNA, and site B contributes
to the cooperative DNA binding by the cGAS dimer. Crosslinking
of the cGAS dimer by dsDNA restricts the structural flexibility of
cGAS and stabilizes the active conformation of the enzyme.
Interactions at the cGAS dimer interface make additional contri-
butions to the DNA binding-induced dimerization or oligomeriza-
tion of cGAS.
Our cell-based reporter assays and enzyme assays via
mcGAS mutants suggest that DNA binding at both site A and
site B as well as the dimerization of cGAS are needed to activate
the enzyme. The two DNA binding sites probably have distinct
contributions to cGAS function. Our mutational analysis showed
that mutations at site A do not consistently affect DNA binding
and that the activities of the mutants do not correlate well with
DNA binding. For example, mutations R158E, K160E, R161E,
and S165E dramatically reduced enzyme activity but only slightly
reduced DNA binding. This suggests that residues involved in
DNA binding at site A probably have two levels of function.
Some residues mainly mediate DNA binding, whereas others
mediate DNA binding-induced conformational changes of
cGAS. Because DNA binding at site A is more extensive and
cGAS binds DNA cooperatively through two binding sites, muta-
tions of individual residues at site A have only limited impact on
DNA binding. However, mutations of key residues such as R158,
K372, K395, and S165 that might mediate cGAS conformational
changes have large impacts on the activity of the enzyme. In
contrast, mutations of key residues at site B have much larger
impacts on DNA binding, demonstrating the critical role of site
B in cooperative DNA binding. Moreover, the impact of muta-
tions at site B on DNA binding correlates with the impact of these
mutations on enzyme activity, suggesting that site B has a
primary role in DNA binding and crosslinking of the cGAS dimer.
Because the enzyme activity assays were carried out under
different enzyme and DNA concentrations with a different buffer,
this may also contribute to the imperfect correlation between theImmresults of enzyme assays and DNA binding studies for some
residues. For example, mutations R222E and K240E dramati-
cally reduced DNA binding, but these mutants still exhibit
some catalytic activity in the context of cGAS catalytic domain
and show almost full activity in cell-based assays with full-length
cGAS. Because the primary roles of these two residues are DNA
binding at site B, the higher DNA and enzyme concentrations
used for the enzyme assays may overcome the effects of these
two mutations. It is also likely that full-length cGAS exhibits
higher affinity for dsDNA that helps to overcome the effect of
these two mutations on cGAS activity in the cells.
It was proposed that cGAS is activated by dsDNA in a similar
manner as OAS1 by dsRNA through a 1:1 cGAS:DNA complex
via site A (Civril et al., 2013; Gao et al., 2013a). The critical roles
of site B in DNA binding and cGAS activation were not investi-
gated in previous studies. In addition to a requirement for site
B, we found that dimerization is required for the DNA-dependent
activity of cGAS. AUC analysis of mcGAS mutant K382A shows
that mutation of K382 at the dimer interface does not affect the
formation of a 1:1 cGAS:dsDNA complex, yet the enzyme is
completely inactive. Notably, cGAS is activated by a mechanism
distinct to that of OAS1 activation by dsRNA (Donovan et al.,
2013). OAS1 does not contain the zinc-binding loop that
mediates the dimerization of cGAS, and dimer formation by
OAS1 was not observed in the crystal structure of OAS1 bound
to dsRNA (Donovan et al., 2013; Hartmann et al., 2003). Further-
more, if cGAS were to form a 1:1 complex with dsDNA via only
site A, short dsDNA of 12 bp should also activate the enzyme
efficiently. As seen in our cGAS:dsDNA complex structures,
only when the length of the dsDNA is greater than 16 bp is it
possible for the DNA to span the two binding sites in a cGAS
dimer effectively, crosslink the cGAS dimer, and activate the
enzyme. Taken together, we conclude that the 2:2 cGAS:dsDNA
complex structure reported here reveals the mechanism of
cGAS activation by dsDNA that has been overlooked by previous
studies (Civril et al., 2013; Gao et al., 2013a).
The structures of cGAS bound to various nucleotides provided
insight into how the enzyme may catalyze the synthesis of 20,50
cGAMP. Although a catalytic mechanism of cGAS has been
proposed based on these structures (Gao et al., 2013a), this
mechanism needs to be tested by further structural studies.
For example, cGAS has high specificity for ATP and GTP as
substrates, but the specificity of the enzyme cannot be fully
explained by the available structures. According to the proposed
mechanism, the reaction intermediate needs to be flipped after
the formation of the 20,50 phosphodiester linkage (Gao et al.,
2013a). It is not clear how this could occur during the reaction.
Moreover, how cGAS catalyzes the synthesis of two different
kinds of phosphodiester bonds remains unknown. It is also not
clear why the product is not released immediately after the
formation of the 30,50 phosphodiester bond, and needs to un-
dergo another flip before its release from the active site.
We have demonstrated that 20,50 cGAMP exhibits higher
affinity for STING compared to canonical bacterial cyclic dinu-
cleotides and is more potent in stimulating IFN-b expression
in cells. However, the mechanism of how 20,50 cGAMP contrib-
utes to enhanced STING binding remains to be established. In
addition, the mechanism of how STING and its natural variants
distinguish between the endogenous second messenger andunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inc. 1029
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Structural Insight of cGAS Activationbacterial analogs is also not clear. Further biochemical and
biophysical characterization of 20,50 cGAMP binding to STING
should provide insight into these questions. Moreover, although
crystal structures of STING bound to c-di-GMP have been
reported (Huang et al., 2012; Ouyang et al., 2012; Shang et al.,
2012; Shu et al., 2012; Yin et al., 2012), crystallographic analysis
of STING bound to 20,50 cGAMP is technically challenging
because STING forms a homodimer but the ligand is asymmet-
rical. Even though two structures of 20,50 cGAMP bound to
STING have been reported (Gao et al., 2013b; Zhang et al.,
2013), the electron density observed in these studies corre-
sponds to the average electron density of 20,50 cGAMP in two
distinct orientations. Therefore, it is still not completely clear
how STING recognizes 20,50 cGAMP. Further binding studies
by NMR or molecular simulations should provide additional
insight into this question.
It has been reported that cGAS, also known as C6orf150, in-
hibits the replication of several viruses (Schoggins et al., 2011).
Recent studies revealed that cGAS synthesizes 20,50 cGAMP to
carry out these functions (Diner et al., 2013). Because 20,50
cGAMP is an endogenous second messenger with a molecular
weight of only 675 Dalton, it has the potential to be used as an
antiviral reagent. Interestingly, our cell-based studies showed
that 20,50 cGAMP added to the culture medium induced IFN-b
production in THP-1 cells, suggesting that the cells can pick
up 20,50 cGAMP added to the culture medium without the use
of liposomes to deliver it into the cytosol. Because the enzymatic
synthesis of 20,50 cGAMP is rather straightforward, this cyclic
dinucleotide has the potential to be used as an immune modu-
lator, such as adjuvant for vaccines, as well as an antiviral or anti-
cancer reagent.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
hcGAS and mcGAS were cloned into a modified pET-28(a) vector with an
N-terminal SUMO tag. The proteins were expressed in E. coli BL21(DE3) at
15C and purified as described (Shu et al., 2012). Mutants of hcGAS and
mcGAS were generated with the QuikChange site-directed mutagenesis kit
(Agilent Technologies). The cGAS mutants were expressed and purified the
same way as the wild-type protein. Human STING ligand binding domain
was expressed and purified as described (Shu et al., 2012).
cGAS Activity Assay
cGAS or its mutants were incubated with DNA in a reaction buffer containing
20 mM HEPES (pH 7.5), 5 mM MgCl2, 2 mM ATP, and 2 mM GTP at 37
C
for 2 hr. The samples were centrifuged, passed through a 10 kD ultrafiltration
filter (Millipore), and analyzed by ion exchange chromatography via a MonoQ
column (GE Healthcare).
Crystallization, Data Collection, and Structural Determination
hcGAS in isolation and mcGAS in complex with DNA (with or without 20,50
cGAMP) were crystallized by the hanging-drop vapor-diffusion method at
4C. Diffraction data for the Se-Met derivative crystals of hcGAS were
collected at the Stanford Synchrotron Radiation Lightsource (SSRL) and
processed with the HKL2000 package (Otwinowski and Minor, 1997). The
structures were determined by SAD via the Phenix package (Adams et al.,
2010). Diffraction data for mcGAS bound to the 18 bp dsDNA were collected
with an RAXIS IV++ detector and processed with the HKL2000 or the Mosflm
package (Winn et al., 2011). The structure was determined by molecular
replacement and refined against the twin_lsq_F target with Phenix. Diffraction
data for themcGAS bound to the 18 bp dsDNA and 20,50 cGAMPwas collected1030 Immunity 39, 1019–1031, December 12, 2013 ª2013 Elsevier Inwith an RAXIS IV++ detector and processed with HKL2000. The structure was
determined by molecular replacement by Phenix.
Small-Angle X-Ray Scattering
Small-angle X-ray scattering (SAXS) experiments were performed at beamline
12ID-B of Advanced Photon Sources (APS). The 2D scattering images were
converted to 1D SAXS curves through azimuthally averaging after solid angle
correction and then normalizing with the intensity of the transmitted X-ray
beam. The radius of gyration (Rg) was calculated by the Guinier equation.
The pair distance distribution function (PDDF) was calculated with GNOM
(Svergun, 1992). Three-dimensional molecular envelopes were calculated
with DAMMIN (Svergun, 1999). Molecular models of hcGAS in isolation and
mcGAS in complex with DNA were docked into the molecular envelope manu-
ally with PyMol.
Analytical Ultracentrifugation
Sedimentation velocity experiments were performed in a Beckman Pro-
teomeLab XL-I at 4C via interference optics. Raw fringe data were deconvo-
luted into sedimentation coefficient or sedimentation coefficient-frictional ratio
distributions via c(s) and c(s,f/f0) models, respectively, in the program Sedfit
(Brown and Schuck, 2006). The c(s,f/f0) analysis deconvolutes complicated
mixtures into a size-and-shape distribution that separately fits the sedimenta-
tion coefficient and frictional ratio for each species, allowing more accurate
determination of putative species based on molecular weights. Values for
buffer density and viscosity and partial specific volume of cGAS were calcu-
lated with Sednterp. The partial specific volume of the cGAS:DNA complex
was calculated as a weight-averaged value of the partial specific volumes
for cGAS and the dsDNA and corrected to 4C by Sednterp.
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Coordinates and structure factors for hcGAS, mcGAS in complex with the
18 bp dsDNA, mcGAS in complex with the 18 bp dsDNA, and 20,50 cGAMP
have been deposited in the Protein Data Bank with accession codes 4LEV,
4LEW, 4LEY, and 4LEZ.
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